<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03106792</url>
  </required_header>
  <id_info>
    <org_study_id>16HHHB</org_study_id>
    <nct_id>NCT03106792</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Effectiveness of Hairfinity on Improving Hair Health and Rate of Growth</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, 4-arm Parallel Study to Evaluate the Effectiveness of Hairfinity on Improving Hair Health and Rate of Growth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brock Beauty Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KGK Synergize Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brock Beauty Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary outcome of the study is the effect of Hairfinity vs. Placebo on the rate of
      distal hair growth, assessed using Trichoscan HD, in healthy female adults from baseline to
      day 90 (end of study).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2017</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of distal hair growth</measure>
    <time_frame>90 days</time_frame>
    <description>assessed using Trichoscan HD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in number of shed hair strands</measure>
    <time_frame>90 days</time_frame>
    <description>assessed using the standardized wash test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean diameter of hair fibers</measure>
    <time_frame>90 days</time_frame>
    <description>assessed using Trichoscan HD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hair density</measure>
    <time_frame>90 days</time_frame>
    <description>assessed using Trichoscan HD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of terminal and vellus hairs</measure>
    <time_frame>90 days</time_frame>
    <description>assessed using Trichoscan HD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the percent of hairs in the anagen and telogen phases</measure>
    <time_frame>90 days</time_frame>
    <description>assessed using Trichoscan HD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hair quality parameters</measure>
    <time_frame>90 days</time_frame>
    <description>assessed by a dermatologist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hair quality</measure>
    <time_frame>90 days</time_frame>
    <description>assessed by a dermatologist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hair quality</measure>
    <time_frame>90 days</time_frame>
    <description>assessed with self-assessment questionnaires</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal vital signs</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal complete blood panel</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal electrolytes</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal kidney function panel</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically significant abnormal liver function panel</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Hairfinity #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hairfinity #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hairfinity #3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hairfinity #1</intervention_name>
    <description>Main Hairfinity formulation</description>
    <arm_group_label>Hairfinity #1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hairfinity #2</intervention_name>
    <description>Variation to main formulation</description>
    <arm_group_label>Hairfinity #2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hairfinity #3</intervention_name>
    <description>Variation to main formulation</description>
    <arm_group_label>Hairfinity #3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>No active ingredients</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female 18-50 years of age (inclusive)

          2. Subject is not of child bearing potential. Defined as females who have had a
             hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural
             or surgically with &gt; 1 year since last menstruation).

             OR

             Female subject of childbearing potential must agree to use a medically approved method
             of birth control and have a negative urine pregnancy test result. Acceptable methods
             of birth control include:

               -  Hormonal contraceptives including oral contraceptives, hormone birth control
                  patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable
                  contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)

               -  Intrauterine devices

               -  Vasectomy of partner

               -  Double Barrier Method

               -  Non-heterosexual lifestyle

          3. Fitzpatrick skin type of I-V (See appendix 3)

          4. Willing to maintain the colour of and style of the hair cut for the duration of the
             study

          5. Willing to maintain shampooing frequency and general hair regime for the duration of
             the study

          6. Willing to not cut hair for the duration of the study

          7. Willing to have area of hair prepped for Trichoscan analysis

          8. Healthy as determined by laboratory results, medical history, and physical exam

          9. Subjects must agree to comply with study procedures

         10. Has given voluntary, written, informed consent to participate in the study

        Exclusion Criteria:

          1. Women who are pregnant, breastfeeding, or planning to become pregnant during the
             course of the trial.

          2. Women who have begun hormonal birth control or hormone replacement within 6 months of
             randomization

          3. Subjects taking natural health products, including multi-vitamins, botanicals and
             other nutraceuticals, within 2 weeks of randomization and for the duration of the
             study

          4. Subjects with Fitzpatrick scores over V, which stems from the sensitivity of the
             testing method (requires a degree of color contrast when evaluating hair relative to
             skin)

          5. Subjects having underwent a form of treatment for thinning hair, including
             prescription drugs or light therapy within 6 months of randomization

          6. Medical history of diagnosed alopecia and/or trichotillomania (compulsive hair
             pulling). Medical history may be assessed by the Qualified Investigator

          7. Subjects currently using hair extensions

          8. Subjects with psoriasis or any active dermatological condition of the scalp at
             randomization that in the opinion of the qualified investigator would interfere with
             the clinical evaluations

          9. Medical history of thyroid disorders or with TSH levels outside the normal range
             (0.4-4.5 Â±0.05) as assessed by the Qualified Investigator

         10. Unstable medical condition as determined by qualified investigator

         11. Clinically significant abnormal lab results at screening will be assessed by the
             Qualified Investigator

         12. History, or current diagnosis of any cancer (except for successfully treated basal
             cell carcinoma in an area other than the scalp) diagnosed less than 5 years prior to
             screening. Subjects with cancer in full remission more than 5 years of diagnosis are
             acceptable.

         13. Alcohol abuse or drug abuse within the past 6 months

         14. Consumption of greater than 2 standard alcoholic drinks per day

         15. Use of medicinal marijuana

         16. Participation in a clinical research trial within 30 days prior to randomization

         17. Allergy or sensitivity to study product and/or it's ingredients

         18. Individuals who are cognitively impaired and/or who are unable to give informed
             consent

         19. Any other condition which in the Investigator's opinion may adversely affect the
             subject's ability to complete the study or its measures or which may pose significant
             risk to the subject (e.g. cardiovascular, renal, lung, diabetes, psychiatric illness,
             bleeding disorders etc)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetyana Pelipyagina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGK Synergize Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mal Evans, PhD</last_name>
    <phone>519-438-9374</phone>
    <phone_ext>239</phone_ext>
    <email>mevans@kgksynergize.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2017</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

